Caroline's Feed
Oct 21, 2014

Actelion lifts 2014 profit view on strong Opsumit launch

ZURICH (Reuters) – Actelion (ATLN.VX: Quote, Profile, Research, Stock Buzz) raised its 2014 earnings guidance on Tuesday for the third time this year, buoyed by a strong start to its new heart and lung drug and better-than-expected profit in the third quarter.

Europe’s biggest biotech company said on Tuesday it was encouraged by the uptake for Opsumit, its new treatment for pulmonary arterial hypertension (PAH), which won approval in the United States and Europe at the end of last year.

Oct 16, 2014

New breast cancer drugs boost sales at Roche

ZURICH (Reuters) – Swiss drugs firm Roche reported better than expected third-quarter sales on Thursday, boosted by a strong performance from its new breast cancer drugs.

The world’s largest maker of cancer drugs said group sales rose 2 percent to 11.78 billion Swiss francs ($12.5 billion), slightly ahead of the average forecast of 11.57 billion given by analysts in a Reuters poll.

Oct 14, 2014

Geberit boosts bathroom range with $1.4 billion Sanitec buy

STOCKHOLM/ZURICH (Reuters) – Switzerland’s Geberit AG (GEBN.VX: Quote, Profile, Research, Stock Buzz) said on Tuesday it would buy Nordic ceramics maker Sanitec Corp (SNTC.ST: Quote, Profile, Research, Stock Buzz) for 9.7 billion Swedish crowns ($1.4 billion) in an all-cash deal to expand its range of bathroom products.

The deal will allow Geberit to complement its installation, flushing and piping systems with Sanitec’s toilets, basins, bathtubs and bidets and extend its lead in revenues over European rivals such as Spain’s Roca and Germany’s Grohe.

Oct 14, 2014

Sonova struggles to convince investors with new hearing aids

ZURICH (Reuters) – Sonova, the world’s biggest hearing aid maker, disappointed some analysts on Tuesday with a range of new products that can connect to mobile phones — but not directly.

Shares in the Swiss company dropped almost 3 percent, as some analysts questioned whether the new products would help the firm recapture market share from rival GN Store Nord, whose Linx device allows users to stream voice and music from their iPhones without the need for an intermediary device.

Oct 6, 2014

Left wingers urge Swiss to reject immigration curbs

BERNE (Reuters) – Drastically limiting immigration in Switzerland would isolate the country by damaging its ties with the European Union, left-wing groups said on Monday, calling on voters to reject the proposal.

Swiss voters will decide in a referendum on Nov. 30 whether they want to cap immigration at just 0.2 percent of the resident population or the equivalent of 16,000 people per year.

Oct 4, 2014

UKIP leader says Cameron’s EU plan a ‘gross deception’

WINTERTHUR Switzerland (Reuters) – The leader of Britain’s anti-EU party UKIP on Saturday predicted that divisions between rich and poor would spell doom for the single currency and the dream of a United States of Europe.

Nigel Farage, head of the United Kingdom Independence Party, told a packed political meeting to rapturous applause:

Oct 4, 2014

Farage says Cameron’s EU plan a ‘gross deception’

WINTERTHUR Switzerland (Reuters) – The leader of Britain’s anti-EU party UKIP on Saturday predicted that divisions between rich and poor would spell doom for the single currency and the dream of a United States of Europe.

Nigel Farage, head of the United Kingdom Independence Party, told a packed political meeting to rapturous applause:

Oct 1, 2014

Liechtenstein prosecutor confirms Corpbank owner under investigation

ZURICH (Reuters) – Liechtenstein authorities have confirmed that they are investigating the businessman at the center of the crisis that has engulfed Bulgaria’s fourth-biggest bank, citing suspicions of money laundering.

The investigation of Tsvetan Vassilev, who owns a majority stake in Corporate Commercial Bank (Corpbank), was instigated after a Liechtenstein bank submitted information to the authorities, Liechtenstein’s chief public prosecutor told Reuters.

Sep 17, 2014

For Roche CEO, celebrating failure is key to success

LONDON, Sept 17 (Reuters) – Roche Chief Executive
Severin Schwan likes to crack open the champagne with his drug
research teams at the end of a big project – especially when
they fail.

As the boss of one of the world’s most successful
pharmaceutical companies, whose leading position in cancer
treatments has propelled its market value to more than $250
billion, it might seem a strange response.

Sep 16, 2014

Roche’s $8 billion InterMune buy not a signal for more big deals

LONDON (Reuters) – Roche’s (ROG.VX: Quote, Profile, Research, Stock Buzz) decision to buy U.S. biotech company InterMune (ITMN.O: Quote, Profile, Research, Stock Buzz) for $8.3 billion last month was “exceptional” and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker’ s chief executive said on Tuesday.

Damping down expectations that Roche could embark on a series of such multibillion-dollar deals to bolster its presence in the treatment of rare diseases, Severin Schwan told Reuters there was no change in the company’s M&A strategy or its likely pace of deal-making.